samedan logo

 
 
spacer
home > ebr > spring 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Proteins, proteins, proteins. They are a main feature in our spring edition of EBR – perhaps not surprisingly, considering the continued increase in adoption to clinical practice of high-value, high-performing protein therapeutics and the need for their manufacture at scale by the biopharmaceutical industry.

Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab would argue that, considering the market size and recent numbers of US and European approvals in these drug classes, the future for mid-size contract development and manufacturing organisations lies in complex proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and proteins for cancer and autoimmune conditions in particular (see full pdf). In their articles, Christian Loch from AVMBioMed (see full pdf) and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full pdf) agree that, at present, proteomics is the best means for capturing this vital information.

AVMBioMed highlight the need to consider the importance of post-translational modification in defining the human protein repertoire, and the Trinean team plus Kris Gavaert and Francis Impens flag the need for further improvements in quality to move proteomics towards a unified regulatory process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evonetix Appoints Colin McCracken as Chief Executive Officer

Cambridge, UK, 13 June 2022: EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement